Early Phase 2 data published in the New England Journal of Medicine in 2023 showed considerable promise, but retatrutide has not yet received approval from the MHRA or EMA
369,370 Genetic disruption of GLP-1R signaling leads to cortical osteopenia and heightened bone fragility, primarily caused by increased bone resorption by osteoclasts
Start With A Consultation GLP-3 is an exciting area of medical research, but patients should be careful about misinformation
[8] [9] Comorbidities and concomitant medicines : Patients with type 2 diabetes particularly those taking insulin or sulfonylureas should discuss timing with their clinical team, as reduced appetite following injection may increase the risk of hypoglycaemia and may require dose adjustment of those medicines
Semaglutide data is clear: when treatment stops, weight regain begins
Compounding is a legitimate, regulated pharmaceutical practice that has existed for a long time